Skip to content
Specimen Atlas of Research Peptides30 plates · MIT
PeptidesDBan atlas
← CataloguePlate XXVIII of XXX
XXVIIIPlate XXVIIIReviewed 2026-04-25

Thymalin

Polypeptide complex (thymus-derived)

also known as Thymalinum, thymus extract Khavinson

Polypeptide complex isolated from calf thymus by the Khavinson group (Saint Petersburg Institute of Bioregulation and Gerontology). Used in Russia for decades to support immune function in elderly and post- treatment patients. Russian clinical trials report restoration of T-cell populations and reduced infection rates. Limited Western data.

§ I

At a glance

Per cycle dose
5–10 mg
[khavinson-2002-thymalin]
Mechanistic
Human
[khavinson-2002-thymalin]
Half-life (est)
Hours
Route

IM · Daily for 5–10 days · 1-2×/year

§ II

Mechanism

Primary target — T-cell precursors + thymus-axis maturation pathway [khavinson-2002-thymalin].

Pathway — Modulation of T-cell differentiation + thymic hormone restoration in age-involuted thymus [khavinson-2002-thymalin].

Downstream effect — Restored T-cell populations, improved immune surveillance, reduced infection rates in elderly [khavinson-2002-thymalin].

Origin — Polypeptide fraction isolated from calf thymus extract [khavinson-2002-thymalin].

§ III

Dosage

Protocols described in the cited literature; not medical advice.

ParameterValue
Standard dose5–10 mg / day IM × 5–10 days [khavinson-2002-thymalin]
FrequencyOnce daily during cycle
Lower / starter dose2.5 mg / day
Evidence basisRussian clinical + in vitro [khavinson-2002-thymalin]
Duration5–10 day cycles, 1–2× per year
ReconstitutionSaline or bacteriostatic water
TimingMorning preferred
Half-lifeHours (estimated)
§ III · b

Reconstitution

A pure mass-to-volume utility. Enter what you have in the vial; the atlas computes the volume per dose. No prescription information.

Inputs
The calculator does pure mass-to-volume math. It does not recommend a dose. Refer to Thymalin's cited literature for protocol specifics.
Volumetric outputFig. C — reconstitution math
Volume per dose
0.050mL
≈ 5.0 units on a U-100 insulin syringe
Concentration
5000
mcg per mL
Doses per vial
40
at this dose
§ V

Adverse events

Severities follow the FDA / CTCAE convention.

Injection site reactionmild
Mild erythema at IM site
Allergic reactionmoderate
Rare hypersensitivity to bovine-derived polypeptide
Autoimmune flaremoderate
Theoretical risk in active autoimmune disease
Long-term safetymoderate
Limited Western data
Pregnancy / OBsevere
Avoid
Absolute contraindications
  • — Pregnancy / breastfeeding
  • — Bovine protein hypersensitivity
Relative contraindications
  • — Active autoimmune disease
  • — Concurrent immunosuppressant therapy
§ VI

Administration

  1. 01
    Reconstitution

    Add 1–2 mL saline or bacteriostatic water per 10 mg vial.

  2. 02
    Injection site

    Intramuscular — deltoid or gluteal. Rotate sites.

  3. 03
    Timing

    Morning preferred during cycle.

  4. 04
    Storage

    Lyophilised: refrigerate, light-protected. Reconstituted: use immediately.

  5. 05
    Needle

    23–25G, 25–38 mm IM needle.

§ VII

Synergies

moderate synergy
+
Thymalin + Thymosin α-1

Thymalin is a polypeptide complex; Thymosin α-1 is a single purified peptide. Both target the thymus-axis but at different levels — Thymalin restores broad thymic signaling; Tα-1 provides a specific molecular activator. Anecdotally combined for elderly immune support.

Primary benefit — Broad thymic restoration + targeted immune activation
Appendix

Sources

30%

of 40 rendered claims carry a resolvable citation.

  1. [camerini-2001-talpha1]
    Camerini 2001 — Thymosin alpha-1: a clinical update
    Curr Opin Investig Drugs, 2001
    Source →
  2. [khavinson-2002-thymalin]
    Khavinson 2002 — Peptides and Ageing
    Neuroendocrinol Lett, 2002
    PubMed →
Plate composed 2026-04-25 · maturity draft · schema v1 · Contributors: peptidesdb-core · 28 fields uncited — open contributions
Edit on GitHub →Read another →